Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) were down 9.8% during trading on Tuesday . The company traded as low as $4.87 and last traded at $4.87, with a volume of 1,446,050 shares traded. The stock had previously closed at $5.40.

A number of analysts have recently commented on PGNX shares. Brean Capital reissued a “buy” rating and set a $14.00 target price on shares of Progenics Pharmaceuticals in a research note on Friday, May 6th. Jefferies Group reissued a “buy” rating on shares of Progenics Pharmaceuticals in a research note on Friday, June 10th. Zacks Investment Research cut shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 6th. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Progenics Pharmaceuticals in a research note on Monday, April 4th. Finally, BTIG Research reissued a “buy” rating and set a $9.00 target price on shares of Progenics Pharmaceuticals in a research note on Wednesday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $10.35.

The firm’s market capitalization is $426.32 million. The stock’s 50 day moving average is $4.83 and its 200 day moving average is $4.69.

Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by $0.05. The company had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $3.27 million. Progenics Pharmaceuticals’s revenue for the quarter was up 908.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.15) EPS. Equities analysts expect that Progenics Pharmaceuticals Inc. will post $0.12 earnings per share for the current year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.